Form 4: Ionis Pharmaceuticals Director Spencer Berthelsen Boosts Stake Through RSU Vesting

Ionis Pharmaceuticals Director Spencer R. Berthelsen acquired 4,079 shares of common stock on July 15, 2025, through the vesting of a Restricted Stock Unit award.

Summary

• Spencer R. Berthelsen, a Director of Ionis Pharmaceuticals Inc. (IONS), acquired 4,079 shares of common stock.
• The acquisition occurred on July 15, 2025, and was a result of the vesting and release of a Restricted Stock Unit (RSU) award.
• Following this transaction, Berthelsen directly owns 156,013 shares of Ionis common stock.
• An additional 70 shares are indirectly owned by his daughter, though Berthelsen disclaims beneficial ownership of these shares.
• Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock or its equivalent cash value.
• Restricted Stock Units vest 100% on either the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date.

Sentiment

Score: 7

Explanation: The filing indicates a routine, positive event where a director's equity compensation vests, increasing their stake in the company. This aligns director interests with shareholders and is a standard, expected occurrence, not indicative of new positive or negative news beyond the compensation itself.

Positives

• Director Spencer R. Berthelsen increased his direct beneficial ownership in Ionis Pharmaceuticals by 4,079 shares, indicating continued alignment with shareholder interests.
• The acquisition was due to the vesting of Restricted Stock Units, a common form of equity compensation that aligns management incentives with company performance.

Future Outlook

NA

Management Comments

• The reporting person disclaims beneficial ownership of all securities held by his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

This Form 4 filing reflects a routine equity compensation event for a director in the biotechnology/pharmaceutical industry, where Restricted Stock Units are a common tool to align executive and director interests with long-term company performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation for directors is a standard practice across the biotechnology and pharmaceutical sectors, similar to companies like Amgen, Gilead Sciences, or Biogen, which also utilize performance-based equity awards to incentivize long-term value creation and retain key talent.
• The vesting schedule and delivery on a specific date post-vesting are typical for such awards.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to increased direct ownership.

Key Dates

Recommendation

Keywords

Ionis Pharmaceuticals, IONS, Spencer R. Berthelsen, Form 4, SEC Filing, Beneficial Ownership, Restricted Stock Unit, RSU, Director, Equity Compensation